Gold Investment Management Ltd. Sells 758 Shares of Amgen Inc. (NASDAQ:AMGN)

Gold Investment Management Ltd. lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 44.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 945 shares of the medical research company’s stock after selling 758 shares during the period. Gold Investment Management Ltd.’s holdings in Amgen were worth $305,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in AMGN. Hershey Financial Advisers LLC acquired a new position in shares of Amgen in the 2nd quarter valued at approximately $30,000. nVerses Capital LLC bought a new stake in Amgen in the 2nd quarter valued at $31,000. Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen in the 2nd quarter valued at about $33,000. Matrix Trust Co bought a new position in shares of Amgen during the third quarter worth about $36,000. Finally, FSA Wealth Management LLC lifted its position in shares of Amgen by 182.0% in the first quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock worth $40,000 after purchasing an additional 91 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $362.00 price target on shares of Amgen in a research report on Thursday, September 26th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $305.00 price target (down previously from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Dbs Bank upgraded Amgen to a “strong-buy” rating in a research note on Monday, September 16th. TD Cowen increased their price objective on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, StockNews.com upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $333.50.

Amgen Price Performance

NASDAQ:AMGN traded up $1.27 during trading hours on Friday, hitting $323.18. The company’s stock had a trading volume of 95,567 shares, compared to its average volume of 2,401,621. The company has a market capitalization of $173.72 billion, a P/E ratio of 41.22, a PEG ratio of 2.79 and a beta of 0.60. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. Amgen Inc. has a twelve month low of $260.52 and a twelve month high of $346.85. The stock has a fifty day simple moving average of $323.96 and a 200-day simple moving average of $316.68.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s revenue was up 23.2% on a year-over-year basis. During the same quarter last year, the firm posted $4.96 earnings per share. On average, analysts anticipate that Amgen Inc. will post 19.51 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 2.78%. The ex-dividend date is Monday, November 18th. Amgen’s payout ratio is 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.